Retrogen

Executive Summary

Retrogen is a US-based genomic services and clinical diagnostics company with over three decades of operational experience since 1992. The company offers a comprehensive suite of services including Sanger sequencing, next-generation sequencing (NGS), and molecular diagnostics, catering to research, academic, and clinical markets. Its clinical diagnostic testing portfolio focuses on women's health, infectious diseases, and non-invasive prenatal testing (NIPT). As a privately held firm founded in 2005 and headquartered in San Diego, Retrogen has established a reputation for reliable genomic analysis and has built a diverse customer base across various institutions. The company operates in a competitive landscape but benefits from its long-standing presence and integrated service offerings. Looking ahead, Retrogen is well-positioned to capitalize on the growing demand for genomic diagnostics. Its expertise in NIPT and infectious disease testing aligns with key healthcare trends. However, as a private company with limited public disclosures, growth prospects are not transparent. The company may seek strategic partnerships or expand its test menu to maintain relevance. Overall, Retrogen represents a steady player in the genomics services sector, but its lack of recent fundraising or major announcements suggests a stable, rather than high-growth, trajectory.

Upcoming Catalysts (preview)

• Q3 2026Launch of expanded NIPT panel targeting new genetic conditions70% success
• Q4 2026Partnership with a major hospital network for infectious disease diagnostics60% success
• TBDRegulatory clearance for a novel molecular diagnostic test (e.g., for an emerging pathogen)50% success